PF-08046033 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer.
The study includes adult participants who have advanced cancers that cannot be removed by surgery or have spread to other parts of the body. These cancers include non-small cell lung cancer, esophageal squamous cell cancer, and melanoma.
The study has two parts:
In the first part, small groups of participants receive increasing doses of the study medicine. This helps researchers find a dose that is safe and suitable for further testing.
Once a suitable dose is identified, the second part enrolls more participants with specific cancer types to better understand the safety of the medicine and whether it shows signs of helping control the cancer.
Participants receive the study medicine through regular treatment cycles and are closely monitored for side effects and how their cancer responds. The information from this study will help researchers decide whether PF-08046033 should be studied further in later-stage clinical trials.
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Small groups of participants receive increasing doses of PF-08046033 to find a safe and suitable dose for further testing
Dose Expansion
More participants with specific cancer types receive the identified suitable dose to better understand safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PF-08046033
How Is the Trial Designed?
10
Treatment groups
Experimental Treatment
PF-08046033: Specified dose IV on specified days
PF-08046033: Specified dose IV on specified days
PF-08046033: Specified dose IV on specified days
Participants will receive PF-08046033 dose level 7 IV.
Participants will receive PF-08046033 dose level 6 IV.
Participants will receive PF-08046033 dose level 5 IV.
Participants will receive PF-08046033 dose level 4 IV.
Participants will receive PF-08046033 dose level 3 IV.
Participants will receive PF-08046033 dose level 2 IV.
Participants will receive PF-08046033 dose level 1 intravenously (IV).
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.